Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.
On Tuesday, Aegerion Pharmaceuticals (AEGR)'s Chief Executive Officer, Marc D. Beer, made a $315,900 purchase of AEGR, buying 10,000 shares at a cost of $31.59 each. Beer was up about 5.4% on the buy at the high point of today's trading session, with AEGR trading as high as $33.29 at last check today. Aegerion Pharmaceuticals is trading up about 0.6% on the day Wednesday. Before this latest buy, Beer purchased AEGR at 2 other times during the past year, for a total cost of $1.36M at an average of $34.12 per share.
And at 8x8 (NASDAQ:EGHT), there was insider buying on Tuesday, by Chief Executive Officer Vikram Verma who purchased 38,000 shares at a cost of $7.42 each, for a total investment of $281,918. Before this latest buy, Verma made one other purchase in the past twelve months, buying $237,325 shares at a cost of $9.49 each. 8x8 is trading up about 2.3% on the day Wednesday. Verma was up about 5.9% on the buy at the high point of today's trading session, with EGHT trading as high as $7.86 at last check today.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.